1 active not recruiting, 1 completed, 1 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Alessandro Doria: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease Sotagliflozin, Placebo - Diabetic Nephropathies, Kidney Failure, Chronic | Phase 3 | Recruiting | Alessandro Doria | 150 | 2024-10-31 | 2026-03-24 |
| A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes Fenofibrate, Placebo - Diabetic Nephropathies | Phase 2 | Active not recruiting | Alessandro Doria | 40 | 2022-01-04 | 2026-02-06 |
| A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes Allopurinol, Placebo - Diabetic Nephropathies, Coronary Artery Disease | Phase 3 | Completed | Alessandro Doria | 530 | 2014-02-01 | 2020-12-04 |
Diabetic Nephropathies (3) · Diabetes Mellitus, Type 1 (2) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Heart Failure (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1)
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (1) · Allopurinol (1) · Fenofibrate (1)
United States (3) · Canada (2) · Denmark (1)
Michael Mauer, MD (3) · David Cherney, MD PhD (1)
PMID 32579810, PMID 39423023, PMID 39727210, PMID 39918875
UC4DK101108-01 (1)